Contact Supplier

Contact Supplier

To get in touch with CD46 knock-out using CRISPR/Cas9 editing of hTERT immortalized human cells modulates complement activation, simply fill out the form below.

Subscribe to Supplier

Subscribe to Supplier

.

CD46 knock-out using CRISPR/Cas9 editing of hTERT immortalized human cells modulates complement activation

white-paperEvercyte GmbH
February 25th 2020

Abstract Summary

The kidney is especially sensitive to diseases associated with over activation of the complement system. While most of these diseases affect kidney glomeruli and the microvasculature, there is also evidence for tubulointerstitial deposition of complement factors.

To learn more about Evercyte’s CD46 knock-out using CRISPR/Cas9 editing of hTERT immortalized human cells modulates complement activation, please download White Paper:

Sources: Matthias Weiser, Teresa Francisci – Evercyte GmbH, Vienna, Austria; Daniel Lackner, Tilmann Buerckstuemmer – Horizon Genomics GmbH; Kamilla Wasner, Markus Wahrmann, Georg A. Bohmig – Department of Medicine III. Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria; Wolf Eilenberg, Anton Stift – Department of Surgery, Medical University of Vienna, Vienna, Austria; Johannes Grillari – Evercyte GmbH, Vienna, Austria / Department of Biotechnology, BOKU Vienna, Vienna, Austria / Austrian Cluster for Tissue Regeneration, Vienna Austria / Christian Doppler Laboratory for Biotechnology of Skin Ageing, Vienna, Austria; Redina-Griari-Voglauer – Evercyte GmbH, Vienna, Austria / Department of Biotechnology, BOKU Vienna, Vienna, Austria / Austrian Cluster for Tissue Regeneration, Vienna Austria.

Contact Evercyte GmbH

Simply fill out the form below to contact Evercyte GmbH now.

Send Evercyte GmbH a Message